RxDoctor Payments DataLook up a doctor →

Thomas Vidic, MD

Neurology · Elkhart, INNPI 1265437404

Payments from drug & device makers

$84,448in general payments, 2019–2025

Across 952 payments — averaging $88.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$34K
  • AbbVie$27K
  • Sunovion Pharmaceuticals Inc.$8K
  • Biogen$1K
  • AstraZeneca$801
  • Bristol Myers Squibb$795
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$7752%
  • Speaking & faculty fees$23,11854%
  • Travel & lodging$1,4473%
  • Food & beverage$17,55141%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.31$34,461
AbbVie(2 entities)122$26,582
Sunovion Pharmaceuticals Inc.27$7,983
Biogen23$1,064
AstraZeneca(2 entities)28$801
Bristol Myers Squibb38$795
Novartis50$780
Jazz Pharmaceuticals Inc.31$724
UCB, Inc.44$700
Genentech USA, Inc.29$690
Catalyst Pharmaceuticals, Inc.27$667
Novo Nordisk45$661
Neurocrine Biosciences, Inc.23$553
Lundbeck LLC22$515
EMD Serono, Inc.30$455
Argenx US, Inc.19$430
Teva Pharmaceuticals USA, Inc.21$406
Johnson & Johnson25$378
Lilly USA, LLC25$374
Amgen(2 entities)18$351
SK Life Science, Inc.16$347
Sanofi16$326
Merck18$298
Vanda Pharmaceuticals Inc.6$283
Banner Life Sciences, LLC13$282
Acadia Pharmaceuticals Inc17$273
Axsome Therapeutics, Inc.10$249
Livanova USA, Inc.22$226
Pfizer14$210
Ipsen Biopharmaceuticals, Inc10$192
Biohaven Pharmaceutical Holding Company Ltd.9$182
Adamas Pharmaceuticals, Inc.11$170
Amneal Pharmaceuticals LLC8$159
Piramal Critical Care9$152
Avanir Pharmaceuticals, Inc.10$152
Mallinckrodt Hospital Products Inc.6$109
Acorda Therapeutics, Inc6$106
TG Therapeutics, Inc.4$99
Idorsia Pharmaceuticals US Inc6$98
Grifols USA, LLC5$85
Supernus Pharmaceuticals, Inc.4$76
Medtronic1$72
Otsuka America Pharmaceutical, Inc.4$67
Abbott4$66
Kyowa Kirin, Inc.3$57
Tanabe Pharma America, Inc.3$55
MDD US Operations, LLC4$55
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$51
Greenwich Biosciences, Inc.3$50
Nevro Corp.1$44
Corium, LLC2$41
Amylyx Pharmaceuticals, Inc.2$41
Cycle Pharmaceuticals Inc2$39
Octapharma USA, Inc.2$37
Merz Pharmaceuticals, LLC2$36
Alnylam Pharmaceuticals Inc.2$35
Xeris Pharmaceuticals, Inc.2$33
Life Molecular Imaging Ltd1$24
Sumitomo Pharma America, Inc.1$20
Biohaven Pharmaceuticals, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,448 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$251,074
Medicare patients
476
Services billed
12,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel111$153,091
VumerityDiroximel Fumarate12$120,305
BetaseronInterferon Beta-1b12$114,527
AustedoDeutetrabenazine16$108,480
Rufinamide34$83,158
XifaxanRifaximin24$59,619
NuedextaDextromethorphan Hbr/Quinidine30$51,379
XcopriCenobamate48$50,092
Aimovig AutoinjectorErenumab-Aooe40$38,188
UbrelvyUbrogepant22$21,626
Glatiramer Acetate14$19,077
Levetiracetam415$17,293
Lacosamide100$17,197
AptiomEslicarbazepine Acetate12$14,338
Memantine Hcl363$13,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$34,461$153,091111 claims
BiogenVumerity$1,064$120,30512 claims
Teva Pharmaceuticals USA, Inc.Austedo$406$108,48016 claims
Avanir Pharmaceuticals, Inc.Nuedexta$152$51,37930 claims
SK Life Science, Inc.Xcopri$347$50,09248 claims
AbbVieUbrelvy$26,582$21,62622 claims
Sunovion Pharmaceuticals Inc.Aptiom$7,983$14,33812 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$159$2,15728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →